Long-standing research has shown that increased lipid content in donor livers is associated with inferior graft outcomes posttransplant. The global epidemic that is obesity has increased the prevalence of steatosis in organ donors, to the extent that it has become one of the main reasons for declining livers for transplantation.
| INTRODUC TI ON
Liver transplantation (LT) is currently the only curative option for end-stage liver disease, or cirrhosis, and early-stage hepatocellular carcinoma.
1,2 However, there is a continuing discrepancy between organ availability and quality and the ever-increasing number of patients eligible for LT. [3] [4] [5] [6] One potential method to bridge this discrepancy is the increased utilization of extended-criteria donors (ECD)
or marginal donors. 3 These donor livers include fatty livers/steatotic livers (referred to as steatotic liver hereafter), donors with advanced age, donor livers with prolonged cold ischemic times (CIT), and donation after circulatory death (DCD). Transplantation of ECD livers is associated with a higher incidence of graft dysfunction, including primary graft nonfunction (PNF), and inferior patient survival after LT. 5, 7, 8 Recently ex situ machine perfusion (MP) of ECD livers has generated considerable interest, with early preclinical and clinical series suggesting it may improve organ preservation, as well as allowing real-time organ function assessment. 9, 10 Indeed, many in the transplant community are suggesting that MP may be a potential method to increase the donor pool. 11 Importantly, steatosis is the primary reason for declining donor livers in the United Kingdom as it is in other countries. 12, 13 Hence, the potential use of MP to reduce steatosis in donor livers and/or improve its metabolic function may be a useful avenue to improve organ utilization for transplantation.
Despite clinical need, the use of MP for steatotic livers still relatively under-researched. The objective of this review was to investigate how MP could be a tool to expand the use of steatotic organs in LT, focusing especially on steatosis reversal (more commonly known as defatting).
| ME THODS
The following databases were searched for the development of this review: PubMed, Web of Science, EMBASE, MEDLINE, Cochrane Library, and Scopus. The literature search was performed until March 1, 2018 and the medical subject heading (MeSH) terms and
Emtree keywords "machine perfusion, liver transplantation" combined with the free text terms "steatosis," "fatty livers," "defatting,"
and "steatosis reversal." The search strategy used is shown in supplementary Table S1 . There was no initial limit of date for inclusion in an attempt to identify most of the papers published.
Two authors (YLB and APCSB) selected the articles independently to include in the review according to the Preferred Reporting Systematic Reviews and Meta-Analyses (PRISMA) protocol. 14 Initially article titles that completely did not match the aims of this review were excluded and the remaining abstracts were analyzed. In this second step, abstracts identified as not relevant were excluded. Finally, full papers that could be retrieved were analyzed and included in the review. Figure 1 provides a flow diagram of the selection process.
Inclusion criteria were (1) articles studying MP and steatotic livers; (2) animal models or human liver experimentation; (3) however, the authors felt it was essential for readers to fully understand the field. No review protocol was registered before starting this review.
| RE SULTS
Fifteen articles met our inclusion/exclusion criteria and are described hereafter. The complete screening process is presented in Figure 1 .
| Steatosis
Obesity is a global issue, and according to the World Health 
| Steatosis classification and grading
Histologically, steatosis is classified as follows: (1) "macrovesicular steatosis" (MaS), which describes the presence of large lipid droplets (LD) within the hepatocyte cytoplasm, which displaces the nucleus;
and (2) "microvesicular steatosis" (MiS), when numerous small LDs can be found in the cytoplasm without any alteration in the position of the nucleus of the cell. In "pure" MiS, small LDs uniformly occupy the whole cell. The former is a rare condition associated with specific conditions (eg, Reye syndrome, acute fatty liver of pregnancy, and mitochondrial hepatopathies) and such livers would not be considered for donation. 18 However, the presence of areas of MiS have been described in nonalcoholic and alcoholic liver disease.
19
Mixed forms of large and small LDs are common in steatotic donor livers and are classified as MaS. 18, 20 Later the terms large-droplet and small-droplet MaS were created to differentiate mixed forms.
21
Large-droplet MaS was used for single LD larger than half of the cell displacing the nucleus; and small-droplet MaS if smaller than half of the cell and not displacing the nucleus. 21 While these new subcategories may better classify steatosis, their nature in relation to pathology remains unclear, with most studies reporting just the presence of MaS and MiS.
Traditionally, MaS has been graded according to the percentage of cells infiltrated by fat as mild ≤30%, moderate 30%-60%, and severe ≥60%. However, there is still no consensus in the literature on the standardization of methods for sample collection or analysis to
The β-oxidation of fatty acids in the mitochondria. Cytosolic fatty acid reacts with adenosine triphosphate (ATP) producing fatty acyl adenylate, which in turn react with free coenzyme A (CoA) originating fatty acyl-CoA. Carnitine palmitoyltransferase I catalyzes the reaction of acyl-CoA with the hydroxyl group of carnitine by carnitine palmitoyltransferase. Acyl-carnitine is transported inside by a carnitine-acyl-CoA transferase and a carnitine is transferred outside. Acyl-CoA is processed by β-oxidation, releasing an acyl-CoA molecule 2 carbons shorter than it was at the beginning of the process, acetyl-CoA, NADH, and FADH2. Acetyl-CoA will undergo the Krebs cycle, releasing more NADH and FADH2. Electrons from NADH and FADH2 will be utilized in the electron transport chain transferring electrons from donors to recipients, and this movement of electrons is linked with transfer of protons (H + ). This electrochemical proton gradient generated is essential in the production of ATP. Complex I (NADH dehydrogenase) and complex III (coenzyme Q) generate superoxide (O 2 − ), which interacts with superoxide dismutase producing hydrogen peroxide (H 2 O 2 ). H 2 O 2 in the presence of transition metals generates hydroxyl radical (HO − ). Hydroxyl radical causes lipid peroxidation in membrane phospholipids, DNA injury that could culminate with cell death. Lipid peroxidation leads to the production of malondialdehyde and 4-hydroxynonenal, which are eliminated from damaged hepatocytes into the space of Disse. Uncoupling protein 2 (UCP2) is overexpressed in the mitochondria of fatty livers, promoting increased leakage of protons (H + ), which dissipates the mitochondrial membrane potential and dissociates the electron transport chain from the oxidative phosphorylation. Lowering the proton gradient UCP2 decreases the generation of superoxide anion at the complex 1 of the electron transport chain 
| Cellular effects of steatosis
Steatosis has several effects upon cellular metabolism. Adenosine triphosphate (ATP) synthesis is impaired, and it has been linked to impaired mitochondrial ATP synthase activity. 23 When exposed to stressful stimuli such as ischemia-reperfusion injury (IRI), these livers demonstrate increased injury relative to nonsteatotic livers. [24] [25] [26] Diminished ATP stores have also been correlated with higher rates of necrosis in steatotic livers during IRI. 27 The mitochondrion plays an integral part in regulating the fate of steatotic hepatocytes. In a normal lean liver, the inner-membrane mitochondrial protein uncoupling protein 2 (UCP2) acts as a mitochondrial antioxidant, dissociating oxidative phosphorylation from ATP production. 28 UCP2 is overexpressed in the mitochondria of fatty livers, promoting increased proton leakage, 29 and it has a direct relationship with reactive oxygen species (ROS) production. 27 Furthermore, UCP2 was also related to necrotic cell death, stalling the cell cycle at the G1 phase and interrupting apoptotic pathways as well as hepatic regeneration. 28 Figure 2 illustrates the complex relationship between UCP2 and the mitochondrial electron transport chain.
| Microcirculation of steatotic livers
Early studies using steatotic rodent livers retrieved and stored cold for 6 hours demonstrated damage to the hepatic microcirculation characterized by narrowing of the hepatic sinusoids relative to lean controls. 30 These changes are caused by a reduced sinusoidal diameter secondary to compression by fat-laden hepatocytes 26, [31] [32] [33] [34] and/or obstruction of the microcirculation by cells or debris as verified by Doppler studies. [33] [34] [35] [36] [37] Indeed, the degree of steatosis correlates with reduced total blood flow as well as the hepatic parenchymal microcirculation in livers histologically classified as moderately or severely steatotic.
37
Microcirculatory dysfunction leads to a "secondary" ischemic hit during reperfusion, allowing the production of more ROS and activation of Kupffer cells. 38 Activated Kupffer cells produce endothelin-1, a vasoconstrictor, in excess of the counterbalance provided by nitric oxide, a vasodilator. Lastly, cytokines released cause endothelial F I G U R E 3 Mechanisms of interaction between fatty loaded hepatocytes and the other cell types of the liver. Microcirculatory dysfunction in fatty livers during reperfusion is a multifactorial process involving complex metabolic pathways. First, ballooned lipid-laden hepatocytes cause a reduction in sinusoidal diameter, which causes a mechanical effect worsening the flow in steatotic livers. During the restoration of blood flow after periods of ischemia, the oxygen on offer overcomes the capacity of the mitochondrial electron transport chain to recover. The dysfunctional electron transport chain leads to a leakage of electrons that will react with oxygen and generate reactive oxygen species (ROS) (superoxide anion, hydrogen peroxide). Kupffer cells will become activated by this production and start a sustained production of endothelin-1 (ET-1), a potent vasoconstrictor associated with inflammatory mediators including ROS, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and chemokines. All these mediators damage the sinusoidal endothelial cells (SEC) and activate the expression of adhesion molecules, which in turn cause accumulation of platelets and leukocytes. Hence, local and systemic inflammatory response will develop with hepatocellular damage dysfunction with expression of adhesion molecules (E-selectin, VCAM-1, and intercellular adhesion molecule-1) and activation, migration, and accumulation of platelets and leukocytes. 39, 40 A summary of these mechanisms is provided in Figure 3 .
| Pro-inflammatory microenvironment within steatotic livers
In experiments using a mouse model of endotoxin liver injury, Kupffer cells from steatotic livers were shown to exhibit lower phagocytic activity and overproduction of ROS, IL-6, and IL-1β, when compared to lean controls. 41 These observations were associated with increased endothelial dysfunction and activation of neutrophils. Persistent activation of these cells enhances the production of ROS and proteases, which aggravate the hepatocellular injury. 
| Impact of steatosis on LT
MiS has been shown to be less deleterious in the setting of LT. Livers with even >60% of MiS were shown to be safe for transplantation in terms of patient and graft survival and a feasible option to expand the pool of donors. 43, 44 This finding can in part be explained by less mechanical compression of the sinusoids by hepatocytes laden with smaller LDs. 45 Early experience with steatotic livers in transplantation was poor, with clinical series demonstrating a high incidence of PNF. 13, 30, [46] [47] [48] [49] [50] Mildly steatotic livers are widely considered to be safe for transplantation as there is no evidence to support increased risk of postoperative complications with the use of these grafts. 51 Studies on the use of moderately steatotic livers describe varying outcomes, particularly with respect to graft survival and early graft dysfunction. [52] [53] [54] [55] [56] [57] [58] [59] Westerkamp et al 60 reported results of transplantation of 19 moderately steatotic livers compared with nonsteatotic in the context of short CIT (<8 hours). Similar patient and graft survival was reported with an increase in the rate of postoperative complications and markers of hepatic injury. 60 A summary of these studies is presented in Table 1 . The lack of standardization for the timing of liver biopsy, type of biopsy (core needle or wedge), staining performed, and definition of MaS is evident. It is important to note that these studies used strict selection criteria for moderately steatotic donor livers, keeping other associated risk factors to a minimum, such as the exclusion or avoidance of moderately steatotic DCD livers, elderly donors, selection of recipients who may cope better with possible delayed graft functioning, and consideration of only steatotic organs with short CIT (6-8 hours). 61 Salizzoni et al 62 were based on low-risk donors and short CIT. 64 Although these authors have suggested that transplantation of those livers can yield acceptable results, these series should be treated with caution because of variability in steatosis quantification and the constraints stated by the authors.
In summary, the current literature suggests that MaS does have a negative impact on outcomes following transplantation, although the studies have variation in the methodology used. 42, 44, 61, 65 To date, the use of these organs relies heavily on the absence of other criteria of donor marginality. However, for clinicians an aging population associated with increasing rates of obesity requires the development of strategies to maximize the utilization of these grafts from the donor pool.
| Steatosis and organ donation
In the literature, the prevalence of steatosis in donor organs ranges from 13% to 28%. 66 Steatosis was the reason for 42% of donor livers being declined for transplantation in Spain in 2000. 67 The National
Health Service annual report on LT revealed that in 2016 in the United Kingdom, 16.6% of the total 1001 livers retrieved in the period of 2015-2016 were not transplanted. 12 More importantly, steatosis was the main reason for declining the liver in 39% of cases.
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Hence, reducing liver steatosis and recovering its function with MP would potentially allow a significant expansion of the donor pool. 
| Ex situ machine perfusion of donor livers
Ex situ MP of donor livers has been demonstrated to be a safe intervention and may improve the liver quality. 10, 68 This beneficial effect may be more apparent in high-risk ECD organs, which are more susceptible to ischemic injury during cold preservation. 9 The 2 most explored techniques of MP are briefly discussed below.
Hypothermic machine perfusion is performed at temperatures close to 10°C using a dual-vessel perfusion (hepatic artery and portal vein) model or a single-vessel perfusion model through the portal vein alone. The perfusate oxygenation may be derived from a nonoxygenated perfusion scheme 69 to a highly oxygenated hypothermic perfusion set-up through the portal vein (HOPE) alone. 70 HOPE was
shown in experimental models to improve mitochondrial function, decreasing the production of ROS and reducing the activation of the inflammatory cascade. 71, 72 Normothermic machine perfusion of the liver (NMP) is performed at 37°C. Its main benefit is its ability to maintain the organ in a near-physiological environment at full metabolism. This allows the assessment of metabolic parameters for liver viability prior to transplantation. 68 Moreover, it also provides a window of opportunity for ex situ pharmacological interventions during preservation with the aim of organ reconditioning.
| Ex situ machine perfusion of steatotic donor livers
There are limited data on the use of MP in steatotic donor livers.
Defatting of steatotic livers is an intuitive idea to allow the utilization of these organs for transplantation. Defatting strategies should not only aim to reduce the triglyceride load in steatotic hepatocytes but would also attempt to improve the organ metabolism and lessen the impact of IRI. Defatting would be achieved enhancing the lipid metabolism, increasing the cellular exportation of intracellular triglyceride as very low-density lipoprotein (VLDL) and the fatty acid mitochondrial β-oxidation. 
| Potential targets for intervention in the lipid metabolism during NMP
Therapeutic targets to manipulate the lipid metabolism during NMP involve mainly the modulation of the production of enzymes involved with oxidation of FA for energy production and/or FA cellular exportation. As a consequence, cytoplasmic lipases play a key role as initiators in the mobilization of intracellular triacylglycerol stores and conversion into FAs and glycerol. 74 Between those lipases, the adipose triglyceride lipase (ATGL) is considered to be the limiting rate factor for intracellular lipolysis in hepatocytes. [75] [76] [77] The FAs released into the cytosol, apart from being a substrate for metabolism, also act as a ligand for nuclear receptors (NR) promoting the transcription of enzymes related to the catabolism and exportation of FAs. 78, 79 In addition, pharmacological interventions can also activate the expression of those NRs and hence modulate the intracellular catabolism of FAs.
75,79
Peroxisome proliferator-activated receptors (PPAR) are a class of NRs that, when activated, promote transcription of hepatic mRNAs related to mitochondrial β-oxidation of FA, such as acyl-CoA oxidase, carnitine palmitoyltransferase-1, liver-FA binding protein, and peroxisomal ketothiolase. 80, 81 The delta-isoform of PPAR is also associated with a concomitant drop in inflammatory marker levels, namely, transforming growth factor-β1, IL-6, monocyte chemoattractant protein 1, TNF-α, and nuclear factor κB1. 82 The α-isoform of PPAR has been shown to decrease serum triglyceride levels as fenofibrate. 83 Moreover, it was shown in obese animal models that PPAR-α transcription levels are increased during regular exercise in comparison with sedentary animals. 81 Another NR associated with lipid metabolism is the pregnane X receptor (PXR). PXR is a NR involved in the cellular elimination of toxic drugs and xenobiotics. 84 Transgenic PXR-knock-out mice were shown to have a reduction in the acyl-CoA oxidase 1 mRNA levels. This enzyme is responsible for the peroxisomal β-oxidation of very-long-chain FA and concomitantly higher protein levels of the gene CYP4A14. In turn, CYP4A14 converts long-chain FA to toxic dicarboxylic acids that will be used for peroxisomal β-oxidation.
Dicarboxylic acid, which accumulates as a consequence of reduced acyl-CoA oxidase 1 peroxisomal β-oxidation, is implicated in mitochondrial damage and steatosis. to its receptor also acts via the cAMP-PKA pathway to promote lipolysis on hepatocytes. Glucagon was shown to reverse hepatic steatosis in rats that receive the hormone in parenteral nutrition. 86 Visfatin or pre-B-cell colony-enhancing factor 1 is an adipokine increased in obesity. It has insulin-mimetic effects in many tissues and enhances the nicotinamide phosphoribosyltransferase activity in the nicotinamide adenine dinucleotide pathway and leads to a decrease in the glucose serum levels. 87, 88 The exact mechanism linking it to lipid metabolism in steatotic livers is not clear yet. 89 These signaling pathways may be targeted by pharmacological and nonpharmacological methods, and these strategies are discussed below. Figure 4 illustrates the interaction between cytoplasmic lipases, hormones, and lipolysis within hepatocytes.
| Defatting strategies

| Nonpharmacological interventions
NMP alone without the administration of additional therapy has been associated with hepatocyte defatting in animal models.
90,91
Jamieson et al 91 , using a porcine model, showed that NMP decreases hepatic steatosis over periods of 24 and 48 hours. Moreover, NMP increased urea production and sustained factor V and bile production with expression of markers for reperfusion injury comparable to normal livers. 91 Nagrath et al 90 reported a 30% reduction in triglyceride content in the liver of rats over a 3-hour period of NMP.
One recent published study with discarded human livers presenting different degrees of steatosis showed that NMP alone for up to 24 hours can increase the lipid content in the perfusate; however, it has not found any histological change in the fatty content of the organs. 92 The authors discuss the divergent findings from animal models associating it with differences across species and the process of chronic fat accumulation in human livers. 
| Pharmacological interventions
In 1989, Pégorier et al demonstrated that glucagon, dibutyryl cyclic AMP, and forskolin induced ketogenesis in newborn rabbit hepatocytes using sodium oleate as a substrate in an l-carnitine-supplemented medium. 93 Forskolin and glucagon modulate adenylate cyclase and stimulate production of the second messenger cyclic AMP(cAMP). cAMP is a secondary messenger, acting as a signal transducer as it is instrumental in providing a link across the cell membrane between extracellular hormone molecules and intracellular processes.
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The androstane receptor ligand Scorparone (6,7-dimethoxycoumarin) was shown to improve the viability of hepatocytes preserved in Euro-Collins solution, with lower levels of malondialdehyde and alanine aminotransferase found in the supernatant. 95 It also has vasodilatory properties, enhancing the production of prostacyclin, which blocks platelet aggregation and possesses oxygen radical scavenger-like properties. 96 Scorparone, used with other drugs in a cocktail, is associated with reversal of hepatocyte steatosis through the higher production of adiponectin and upregulation of PPAR-γ. 97 Defatting cocktail In addition, they reported a 32% reduction in ROS production, 27%
increase in ATP levels, and high cell viability with lower lactate dehydrogenase (LDH) release. This suggested improved resistance of the treated cells to IRI.
98
The same protocol was later applied to human hepatoma cells hours under static conditions. They concluded that the transport of l-carnitine, which supplies free FA to the mitochondria, is a key factor in the modulation of defatting under flow conditions and flow rates should be adequate enough to ensure that this is delivered to the cells. 100 Liu et al 101 attempted to defat rat steatotic livers using the cocktail at midthermic temperatures. 101 Steatotic livers were perfused using a model of MP at 20°C for 6 hours. VLDL and triglyceride concentrations increased in the perfusate of the vehicle and drug group. However, no significant changes were observed in histology and intracellular triglyceride content at 20°C. It was concluded that the defatting is a process dependent on physiological temperatures (with the metabolism of the organ in full swing) to be effective.
101
Glial cell line-derived neurotrophic factor
Another pharmacological defatting intervention reported in the literature is the use of glial cell line-derived neurotrophic factor (GDNF). This growth factor is involved in the development of enteric nervous cells and it has been shown to optimize glucose control in rats by promoting pancreatic β-cell proliferation.
102 GDNF transgenic mice, which overexpress GDNF, were fed a fatty-rich diet and exhibited resistance to weight gain, diminished insulin resistance, dyslipidemia, hyperleptinemia, and less hepatic steatosis. cells that were made fatty by supplementation with palmitic acid.
They exposed the fatty cells to 48 hours of incubation with 100 ng/ mL GDNF and observed a reduction in intracellular triglyceride content, reaching levels similar to lean cells. However, it should be highlighted that these cells are not primary human hepatocytes and this response could be different. Furthermore, using a model of NMP, the authors perfused 4 fatty mice livers for 4 hours with GDNF in the perfusate and reported an effective reduction of 40% in intracellular lipid content. Another interesting point of this study was that fatty livers were also perfused using the defatting combination of drugs described by Nagrath et al in 2009 and showed that GDNF was effective in clearing LD, decreasing intracellular triglyceride levels, and leaving less LDH in the perfusate. 104 Hence, GDNF may be a promising option for defatting steatotic livers, although the latter study did not include histological analysis of livers subjected to defatting strategies.
Large-animal models of steatosis (eg pigs) would potentially be more reliable for further investigations as they present metabolic functions closer to human livers. 105 However, despite 1 study reporting successful induction of steatosis in pigs using a proteindeficient diet, to our knowledge, no other studies have explored or
reported on similar models. 
80,81
The cocktail of drugs increased mRNA levels of triacylglycerol hydrolase, apolipoprotein B−100, carnitine palmitoyltransferase I, and acyl coenzyme A oxidase.
90
The delta-isoform of PPAR is also associated with a concomitant drop in inflammatory marker levels, namely, transforming growth factor-β1, interleukin-6, monocyte chemoattractant protein 1, tumor necrosis factor-α, and nuclear factor κ B1. 82 
Pregnane X receptor (PXR) ligand Hypericin
Increased peroxisomal β-oxidation of very long chain fatty acids via higher acyl-CoA oxidase 1 (Acox−1) mRNA levels and concomitantly higher protein levels of the gene CYP4A14. In turn, CYP4A14 converts long-chain fatty acids to toxic dicarboxylic acids that will be used for peroxisomal β-oxidation.
84,85
Constitutive androstane receptor ligand Scorparone
Upregulation of PPAR-γ a .
97
Vasodilatory properties, enhancing the production of prostacyclin, which blocks platelet aggregation and possesses oxygen radicals scavenger-like properties. 96 Glucagon mimetic cAMP activator forskolin
Increased lipolysis of lipid droplets in hepatocytes and cellular oxidation of fatty acids.
94
Insulin-mimetic adipokine visfatin Not established.
89
Enhances nicotinamide phosphoribosyltransferase (Nampt) activity in the nicotinamide adenine dinucleotide (NAD+) pathway and leads to a decrease in the glucose serum levels. 87, 88 Glial cell line-derived neurotrophic factor (GDNF)
Peroxisome proliferator-activated receptor-α and 
| Other potential strategies to rescue steatotic organs
The main target for the use of MP in steatotic livers nevertheless
should not be only defatting; instead MP should rescue their metabolic parameters into limits considered safe for transplantation.
Preconditioning of steatotic livers using hypothermic machine perfusion (HMP) or midthermic machine perfusions may improve their metabolic activity and enable them to negate IRI. 
| Hypothermic perfusion and steatotic livers
Bessems et al 109 , using a murine model, reported that hypothermically perfused steatotic livers had a higher rate of bile production, ammonia clearance, urea production, oxygen consumption, and recovery of ATP levels in comparison with SCS. Kron between steatotic livers and "transplantable" discarded livers.
111
In contrast to the former, nontransplantable steatotic organs presented with irreversible mitochondrial damage on electron microscopy at the end of 24-hour perfusion. 
| Midthermic MP and steatotic livers
Midthermic MP at 20°C was shown in experimental rat models to offer beneficial preservation for steatotic organs in comparison with SCS by potentially optimizing energy status. 112 It was also suggested to play a protective role in IRI by decreasing TNF-α, caspase-3 activity thus being associated with lower levels of oxidative injury and damage to the intrahepatic biliary tree. [113] [114] [115] Conversely, in another study examining the metabolic profiles of discarded human livers perfused for 3 hours at 20°C, steatotic livers were found to show higher expression of markers of injury, impaired ATP recovery rate, and higher hepatic artery flow resistance. 116 Importantly, these studies were performed in nontransplant models and further highlight the differences between human livers and current animal models.
| Other strategies to lessen ischemiareperfusion injury
Pharmacological strategies to lessen the impact of organ injury during reperfusion can also be a means of overcoming the risks associated with steatotic livers. A prominent example is the proposed use of the antibiotics minocycline and the cyclophilin inhibitor NIM811.
These have been shown in a rodent model to promote preservation of mitochondrial polarization and lower activation of apoptosis/ necrosis pathways with higher graft survival rates. 117 NIM811 has also associated with better liver regeneration after extended hepatectomy, blocking ATP depletion and activation of cell apoptosis. 
| D ISCUSS I ON
In this review, we described how the cellular changes induced by steatosis could translate into a higher incidence of posttransplant complications. The evidence for the clinical use of these organs and the current "other risk factor minimization strategy" was briefly explored. However, despite this approach being already known by transplant surgeons, steatosis remains a major reason for discarding livers worldwide. 12 MP has a potential role to increase organ utilization by offering opportunities for organ reconditioning and functional assessment. 9, 11 Therefore, the use of this device for preconditioning steatotic donor livers deserves urgent attention. The current evidence suggests that the key point for its safe utilization is avoidance of detrimental effects of IRI. Defatting involves pharmacological modulation of intracellular metabolic pathways.
Enhancing lipolysis intracellular triglycerides stores serve as the substrate for energy production and ligands for nuclear receptors optimizing mitochondrial function. It also leads to lower production of ROS, release of markers of cellular injury, and improved cell viability. 90, 104 Moreover, there is the potential to improve the hepatic microcirculation, lower activation of Kupffer cells, and decrease release of inflammatory mediators during reperfusion, resulting in less subsequent tissue injury. Finally, improvements in organ functioning may potentially be observed during NMP. 107 At present, the studies investigating defatting strategies have focused heavily upon animal models, and the extrapolation of these to the clinical setting is in need of urgent investigation. The same applies to steatotic livers and MP, where only a few studies are available. Data from clinical series of transplantation of steatotic livers are highly heterogeneous. Hence, although we have used a comprehensive search strategy, only a few studies addressed this subject; therefore, the risk of bias within the literature needs to be borne in mind.
Other strategies described also have the potential to limit the detrimental impact of IRI on highly vulnerable steatotic donor livers. The ideal method of MP to improve their utilization still requires definition because comparative clinical data are lacking. This highlights the major limitation of the present review. In addition, it is difficult to make firm conclusions regarding steatotic organ utilization because the definition of MaS, technique for liver biopsy, and steatosis assessment are not standardized among studies. 
| CON CLUS ION
